Amyotrophic lateral sclerosis (ALS) is characterized by the selective death of motor neurons in the motor cortex, brainstem and spinal cord. It is a neurodegenerative disorder with high genetic and phenotypic variability. In most patients, the cause of the disease is unknown. Until now, no treatment strategy has been discovered with the exception of riluzole which has a moderate effect on the disease process. While developing a new causal therapy targeting a specific disease-causing gene can have a huge effect on the disease process, only a limited number of ALS patients will benefit from such a therapy. Alternatively, pathogenic processes that are common in ALS patients with different etiology can also be targeted. The effect of such a modifying treatment will be smaller, but the target population will be larger as more ALS patients could benefit. In this review, we summarize the evidence for the involvement of different biological processes in the pathogenesis of ALS and will discuss how strategies influencing these processes can be translated into new therapeutic approaches. In order to further improve this translational step, there is an urgent need for a better understanding of the underlying mechanism(s), for new ALS animal models and for rigorous protocols to perform preclinical studies.
Introduction
Amyotrophic lateral sclerosis (ALS) is an adult-onset neurodegenerative disorder characterized by selective motor neuron death. Both upper motor neurons in the motor cortex and lower motor neurons in the brainstem and in the ventral horn of the spinal cord are affected. Patients develop a progressive muscle phenotype characterized by spasticity, hyperreflexia, fasciculations, muscle atrophy and paralysis. ALS is usually fatal within 3 to 5 years after the diagnosis (Cudkowicz et al., 1997) .
In most cases (~90%), there is no family history of ALS and these patients are classified as sporadic ALS (SALS) patients. However, a clear family history is present in approximately 10% of ALS patients, and these patients suffer from familial ALS (FALS) . Although the disease is in almost all cases inherited in an autosomal dominant way, also autosomal recessive and X-linked forms exist. Mutations in more than 10 different genes are known to cause FALS (reviewed in (Renton et al., 2014) ). The most common ones are found in the genes encoding superoxide dismutase 1 (SOD1;~20%), fused in sarcoma (FUS; 1-5%) and TDP-43 (TARDBP; 1-5%). Recently, a hexanucleotide repeat expansion (GGGGCC) n in the C9ORF72 gene was identified as the most frequent cause of FALS (~40%) in the Western population (DeJesus-Hernandez et al., 2011; Renton et al., 2011) .
Not only genetically, but also clinically, ALS is a heterogeneous disease. The age and site of onset, the rate of progression and the presence and degree of cognitive dysfunction are variable. In some patients, also neurons in the prefrontal and temporal cortex are affected. This leads to cognitive and/or behavioral problems. These can be very subtle, but in about 15% of ALS patients frontotemporal dementia (FTD) is present, the main symptom of frontotemporal lobe degeneration (FTLD). These patients are diagnosed as suffering from ALS-FTLD (Lillo and Hodges, 2009; Ringholz et al., 2005) . On the other hand, 15% of FTLD patients show signs of motor neuron degeneration (Burrell et al., 2011; Lomen-Hoerth et al., 2002) . This suggests that ALS and FTLD are at the ends of a disease spectrum. This is also reflected by gene mutations that are common to both diseases (e.g. C9ORF72 and valosin containing protein (VCP)) and by a similar neuropathology (e.g. TDP-43 aggregates). The large variation in disease presentation is even observed in families with the same causal gene mutation. This strongly suggests that there are factors, environmental or genetic in nature, that modify the clinical phenotype of the disease. Genetic modifiers of ALS are those genes that influence the severity of the disease process or those that affect the risk for developing ALS. As a consequence, these genes are very important as they could account for the clinical variability in ALS and could also play an important role in the susceptibility for SALS.
Currently, there is no curative treatment for ALS. In 1995, riluzole was approved by the US Food and Drug Administration (FDA) for the treatment of ALS (Bensimon et al., 1994) . Almost two decades later, this drug remains the only approved treatment. Riluzole increases the life span of the patients with an average of 2-3 months (Miller et al., , 2012 , an effect that was reproduced in different clinical trials (Bensimon et al., 1994 (Bensimon et al., , 2002 Lacomblez et al., 1996; Yanagisawa and Shindo, 1996) . As a consequence, the search for new and better treatment strategies for ALS is a top priority. The hope is to find additional treatments that have cumulative effects to riluzole and that can halt the disease process in an early state. The search for these new treatment strategies is facilitated by the availability of good rodent models for ALS. A number of animal models were created that faithfully reproduce the human disease (reviewed in (McGoldrick et al., 2013) ).
The first generated mouse model overexpresses the human SOD1 gene containing a substitution of glycine to alanine at position 93 (SOD1
G93A
) under the control of the human SOD1 promoter (Gurney et al., 1994) . This ubiquitous overexpression of human mutant SOD1 causes a progressive motor phenotype that resembles the human disease and it is considered as the best rodent model so far. Extensive efforts were made to generate other rodent models that recapitulate ALS, using other mutations in the SOD1, TDP-43, or FUS gene. Whereas SOD1 mouse and rat models overexpressing different missense mutations result in an adult-onset and progressive neurodegeneration, most of the TDP-43 and FUS models generated so far show an axonopathy and muscle atrophy but hardly any of these show extensive motor neuron death. As a consequence, rodent mutant SOD1 models are the most frequently used models in translational research as these are the ones that best resemble clinically and pathologically the human situation.
Our expanding knowledge of both the biology of ALS and delivery strategies for drugs in the nervous system has resulted in a number of potential therapeutic strategies. Based on their target, these strategies can be subdivided into two main categories: causal or modifying treatments. While the first type of strategies aims to directly target disease-causing genes in order to avoid their expression and pathogenic effects, the second one targets factors or mechanisms that influence pathological processes related to ALS.
In this review, we will discuss a number of examples to illustrate how strategies influencing different biological processes involved in ALS can be translated into therapeutic approaches. We will summarize the most promising attempts to develop causal treatment strategies, while the main focus of this review is on the efforts to obtain disease-modifying therapies. We will discuss the problems that arise when potential therapeutic strategies are investigated at the preclinical level as well as strategies that could improve the success of this translational step.
Causal treatments
Curing neurodegenerative diseases could be extremely difficult as the damage caused by the disease process seems to be irreversible. However, using a number of conditional animal models for different neurodegenerative diseases it has been shown that it is possible to reverse the disease phenotype if the expression of the mutant gene causing the disease is halted. The first evidence was published in 2000 by Yamamoto et al. using a mouse model of Huntington's disease using a tetracycline-controlled system (Yamamoto et al., 2000) . Turning off the expression of the mutated transgene after disease onset resulted in an almost complete reversal of the disease phenotype as well as in the clearance of the aggregates that are the histopathological hallmark of the disease (Yamamoto et al., 2000) . Similar effects were observed in two mouse models for different types of spinocerebellar ataxia (SCA), SCA1 and SCA7, in which a reduction of the mutant gene expression in symptomatic mice could halt and even reverse the disease phenotype (Furrer et al., 2013; Zu et al., 2004) . In ALS, a partial reversal of the motor phenotype after silencing of the transgene was observed in a TDP-43 overexpressing rats. Cell-type specific overexpression of human mutant TDP-43 in rat, using a tetracyclinecontrolled system, caused progressive paralysis with loss of motor neurons in the ventral horn of the spinal cord (Huang et al., 2012) . Disease progression was halted and functional motor improvement occurred after mutant gene expression was switched off (Huang et al., 2012) .
These findings strongly suggest that motor neuron degeneration can be stopped and that symptoms can be reversed if expression of the mutant protein is prevented. Two different strategies are used to obtain this goal. First, expression of genes can be stopped by using gene silencing methods. Silencing of the SOD1 gene by using antisense oligonucleotides (ASOs) or small interfering RNAs (siRNAs) is effective in different studies using the SOD1 mouse model (Ralph et al., 2005; Raoul et al., 2005; Rizvanov et al., 2009; Smith et al., 2006) . A first attempt is made to translate this approach to patients. Intrathecal delivery of SOD1 antisense oligonucleotides is in a Phase I clinical study, and so far this seems to be well tolerated by patients . Second, mutant proteins can be cleared by specifically designed antibodies. Passive and active immunization against misfolded SOD1 shows therapeutic potential in mouse models (Gros-Louis et al., 2010; Liu et al., 2012; Urushitani et al., 2007) . The generated antibodies enhance the degradation of misfolded protein, and delay the onset and progression of the disease in the SOD1 mouse model.
Due to the lack of animal models for the different etiologies of ALS, causal therapies have not yet been explored for the pathogenic ALS mutations in other genes. The discovery of the technique to generate human induced pluripotent stem cells (iPSCs) (Takahashi and Yamanaka, 2006) paves the way to model the disease caused by these mutations in vitro (Almeida et al., 2013; Bilican et al., 2012; Dimos et al., 2008; Donnelly et al., 2013; Egawa et al., 2012; Sareen et al., 2013; Zhang et al., 2013b) and to explore potential causal therapies. Because of the importance of C9ORF72 repeat expansion in ALS, recent attempts have mainly focused on targeting C9ORF72 transcripts by antisense interventions (Donnelly et al., 2013; Sareen et al., 2013) .
Modifying treatments
The aim of modifying treatment strategies is to interfere with pathological mechanisms that play a crucial role in the disease process, and when targeted have a beneficial effect on disease progression. Many mechanisms have already been suggested to play a role in the pathogenesis of ALS. These include, amongst others, astrocytosis, neuroinflammation, mitochondrial dysfunction, deregulated autophagy, and axonal transport dysfunction and retraction. As modulating these different disease processes could have a positive effect on disease progression, we will give an overview of these pathogenic processes, illustrate with some examples how these can be modified and discuss whether these strategies have been or could be translated into new therapies.
Pathogenic role of non-neuronal cells
ALS is considered as a non-cell autonomous disorder, as expression of mutant SOD1 exclusively in motor neurons does not seem to be sufficient to cause the disease (Beers et al., 2006; Gong et al., 2000; Lino et al., 2002; Pramatarova et al., 2001 ). On the contrary, deletion of mutant SOD1 in motor neurons delays disease onset, while deletion of mutant SOD1 in astrocytes and microglia slows down disease progression (Boillee et al., 2006; Yamanaka et al., 2008) . These studies suggest that expression of mutant SOD1 in neurons is needed for the disease to occur, and that other surrounding cells play an important role in the neurodegeneration and especially in the progression of the disease. Additional evidence for a role of non-neuronal cells was presented in a study using chimeric mice with mixtures of normal and mutant SOD1 expressing cells. Mutant SOD1 containing motor neurons surrounded by normal glial cells, showed a prolonged survival (Clement et al., 2003) . These results suggest a significant role in the pathogenesis for astrocytes and microglia. In addition, it was recently shown that also oligodendrocytes play an important role in the disease process (Kang et al., 2013) .
Astrocytosis
Astrocytes are glial fibrillary acid protein (GFAP)-expressing ectodermal cells that are very abundant in the nervous system and that play an important role in supporting neuronal function. Among others, astrocytes provide neurons with nutrients, metabolic precursors and trophic factors, and regulate the potassium homeostasis and the uptake and catabolism of several amino acids, such as glutamate, released by neurons (Lobsiger and Cleveland, 2007) (Fig. 1) .
The specific contribution of astrocytes in ALS has been demonstrated in vivo and in vitro. Specific deletion of mutant SOD1 in astrocytes significantly extends survival of mutant SOD1 mice (Yamanaka et al., 2008) . Moreover, motor neuron death occurred when co-culturing mouse embryonic stem cell-derived motor neurons with astrocytes derived from mutant SOD1 mice (Di Giorgio et al., 2007) or post-mortem spinal cord neural progenitor cells (NPCs) from SALS or FALS patients (Haidet-Phillips et al., 2011) .
Astrocytes acquire an activated state during disease and the number of activated astrocytes correlates with disease progression (Hall et al., 1998) . Activated astrocytes lose their normal beneficial effects (reviewed in (Philips and Robberecht, 2011) ).
On one hand, astrocytes release toxic factors and secrete reactive oxygen and nitrogen species. Until now, the identity of these toxic factors is largely unknown, although evidence exists for the soluble nature of these factors. This is indicated by the fact that culturing primary motor neurons of embryonic stem cell derived motor neurons with only the mutant astrocyte conditioned medium is toxic for the neurons . Additional efforts are necessary to elucidate the identity of these toxic factors before this knowledge can result in new therapeutic approaches.
On the other hand, mutant SOD1 expressing astrocytes can also fail in protecting neurons from excitotoxicity. In patients and mutant SOD1 mice, the expression of the glial glutamate transporters is decreased Rothstein et al., 1995) . In addition, astrocytes can increase the excitability and calcium influx by increasing the sodium current or by decreasing the neuronal GluR2 expression responsible for a higher calcium permeability of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor, ultimately leading to neuronal excitotoxicity (Fritz et al., 2013; Van Damme et al., 2007) .
Restoring the levels of the glial glutamate transporters in astrocytes was suggested as a possible treatment strategy (Rothstein et al., 2005) . Presymptomatic administration of ceftriaxone, a compound increasing the expression of glial glutamate transporters in astrocytes, prolongs survival in the mutant SOD1 mouse model (Rothstein et al., 2005) . Although phase I and II clinical trials were successful (Berry et al., 2013) , a phase III clinical trial investigating the effect of ceftriaxone was negative (Cudkowicz et al., 2012) . Besides the restoration of intrinsic astrocytic properties, an enrichment of the spinal cord with healthy astrocytes is another strategy under exploration. The focal intraspinal administration of 'Glial-Restricted Precursors' (GRPs) derived from rodent spinal cord attenuated motor neuron loss and extended survival in a mutant SOD1 model . Interestingly, a subsequent study confirmed the survival and proper differentiation of human-derived GRPs transplanted in the spinal cord of a mutant SOD1 model (Lepore et al., 2011) .
Microgliosis
Microglia are 'Cluster of Differentiation molecule 11b' (CD11b) expressing mesenchymal cells and are the local macrophages of the nervous system. Using their processes, microglia constantly screen the extracellular environment for potentially dangerous components (reviewed in (Philips and Robberecht, 2011) . These cells are in close contact with neurons and astrocytes ( Fig. 1) . Microglia are actively contributing to the disease pathogenesis, as specific deletion of mutant SOD1 in the microglia significantly prolongs survival (Boillee et al., 2006) . Similar to astrocytes, microglia also acquire an activated state during the disease process (Turner et al., 2004) . The cell body enlarges and the processes get thicker. They get properties of antigen-presenting cells and start to interact with T-cells, which infiltrate in the affected spinal cord and cortex (Alexianu et al., 2001; Engelhardt et al., 1993) . This microglial activation starts shortly before disease onset and the number of activated glia and infiltrated T-cells increases with disease progression (Alexianu et al., 2001; Beers et al., 2008; Chiu et al., 2008; Gowing et al., 2008; Hall et al., 1998) . The functional alterations that accompany these inflammatory events could contribute to motor neuron death.
Reactive microglia can have two different appearances: a rather neurotoxic one (M1 microglia) and a rather neurotrophic one (M2 microglia) (Kigerl et al., 2009 ). M2 microglia mainly secrete trophic and anti-inflammatory factors, while M1 microglia secrete not only pro-inflammatory molecules but also reactive oxygen species (ROS). During disease progression, the microglial cell population changes from M2 microglia to more neurotoxic M1 microglia, as was shown in post-mortem patient material and in the mutant SOD1 mouse model (Beers et al., 2008 (Beers et al., , 2011 Liao et al., 2012) .
The appearance of either M1 or M2 microglia might depend on the T-cell subtype that is mainly present in the spinal cord after infiltration. Reciprocal signals between T-cells and microglia regulate their appearance and phenotype (Gao and Tsirka, 2011) . T-cells could secrete different subtype-specific interleukines and cytokines that might induce either a shift to the neuroprotective or to the neurotoxic state of microglia. During an early ALS phase, regulatory T (Treg) cells are abundantly present in the spinal cord, which might maintain microglia in an anti-inflammatory M2 state (Beers et al., 2011) . In later disease stages, the number of Treg cells decreases, whereas microglia shift to a more neurotoxic state (M1) (Beers et al., 2011) . These alterations in T-cell subtypes are not only present in mouse models, but also in blood samples of ALS patients (Beers et al., 2011; Henkel et al., 2013) . All together, these data indicate that subsets of T-cells can be important in disease progression.
Different strategies that target inflammation have already been investigated in ALS mouse models and in patients. General immunosuppression or immunomodulation was ineffective (reviewed in (Philips and Robberecht, 2011) ). Administration of minocycline, a compound that reduces microglial activation, delayed onset and prolonged the survival in mutant SOD1 mouse models (Kriz et al., 2002; Van Den Bosch et al., 2002; Zhu et al., 2002) . However, this compound failed in a Phase III clinical trial (Gordon et al., 2007) , although questions were raised concerning the trial design (Leigh et al., 2008) . Moreover, a later study in which SOD1 mice were treated with minocycline after disease onset did not show a beneficial effect on disease progression (Keller et al., 2011) . As most patients in clinical trials were treated after disease onset, this could be another explanation for the negative outcome of the minocycline trial. Celecoxib, a cyclooxygenase 2 (cox2) inhibitor, was effective in the mutant SOD1 mouse model, but not in patients (Cudkowicz et al., 2006; Drachman et al., 2002) . Attempts to neutralize the released ROS with vitamin E, creatine or coenzyme Q10 (CoQ10) were unsuccessful in patients (Galbussera et al., 2006; Kaufmann et al., 2009; Shefner et al., 2004) . Also the modulation of Tcell properties and function with glatiramer acetate failed in clinical trials (Meininger et al., 2009 ). Because of the dual nature of microglia, immunotherapies that suppress the neurotoxic state and retain or promote the protective functions could form a novel strategy to treat ALS. One possibility is a specific approach to enhance levels of Treg. A passive transfer of early phase mutant SOD1 Treg cells prolongs the early disease phase in SOD1 mice, by increasing M2 markers and suppressing M1 markers and pro-inflammatory cytokines (Beers et al., 2011) . Moreover, these cells provide neurons with lactate which is released by the monocarboxylate transporter-1 (MCT-1). 2 Neurotrophic factors are released by several cell types in the nervous system and are required for the normal functioning of neurons. 3 Mitochondria are important for energy metabolism, intracellular calcium homeostasis and apoptosis. 4 Autophagy is one of the major clearance pathways in neurons. It is involved in the degradation of long-living proteins, abnormally folded proteins and for organelle turnover. 5 Neurons are heavily dependent on well-organized transport mechanisms in the long axons. 6 In the peripheral nervous system (PNS), the axon of the motor neuron connects to the muscle at the neuromuscular junction.
Oligodendrocyte dysfunction Oligodendrocytes are glial cells responsible for the myelination of axons in the central nervous system (CNS). Moreover, oligodendrocytes provide neuronal cells trophic support by the release of lactate. This release is mediated by the monocarboxylate transporter-1 (MCT1) (Lee et al., 2012b) (Fig. 1) . It was recently shown that oligodendrocytes play a role in neurodegeneration during ALS (Kang et al., 2013; Lee et al., 2012b; Philips et al., 2013) . While oligodendrocyte numbers remain the same (Kang et al., 2013; Philips et al., 2013) , MCT1 levels are significantly decreased in ALS patients and in ALS rodent models (Lee et al., 2012b; Philips et al., 2013) . In the mutant SOD1 mouse model, oligodendrocytes start to degenerate before disease onset and are replaced by new oligodendrocytes that arise from precursor cells with enhanced proliferation and differentiation rate, also known as NG2 + cells (Kang et al., 2013; Magnus et al., 2008; Philips et al., 2013) . These new oligodendrocytes have morphologic abnormalities and are not fully differentiated (Kang et al., 2013) . Moreover, expression of MCT1 and myelin basic protein (MBP) is strongly reduced, rendering them dysfunctional in trophic support and in myelination (Kang et al., 2013; Philips et al., 2013) . As a consequence, these new not fully mature oligodendrocytes are not able to keep the motor neurons alive (Lee et al., 2012b) . Strikingly, specific deletion of mutant SOD1 in the oligodendrocytes of mutant SOD1 mice significantly delays disease onset and survival. Disease duration is not affected indicating that prolonged survival mainly results from the delay in disease onset. MCT1 expression in those mice was preserved (Kang et al., 2013) . These data indicate that strategies that induce the differentiation of NG2 + precursor cells into fully differentiated oligodendrocytes could have therapeutic potential.
Altered neurotrophic support
Neurotrophic factors are naturally occurring proteins that are essential for neuronal survival and differentiation during development. They are also required for normal functioning of the adult nervous system by influencing dendrite and synapse formation, proliferation, migration and differentiation of stem cells during neurogenesis (Fig. 1) . Neurotrophic factors also play an important role in the repair and maintenance of neurons and their axons during disease or injury of the nervous system (Henriques et al., 2010; . Increased or decreased levels of neurotrophic factors and/or their receptors are observed in spinal cord and brain tissues of ALS patients (Ekestern, 2004) . Due to the high complexity of the system, it is difficult to define a clear pathological role for these neurotrophic changes during ALS. However, the administration of neurotrophic factors can be an important therapeutic tool to increase the maintenance of neurons and their connections. One example of such neurotrophic factor that can modify ALS and that is currently tested in clinical trials is vascular endothelial growth factor (VEGF). VEGF plays a crucial role in the formation of new blood vessels during embryonic development and in hypoxic conditions (reviewed in (Carmeliet and Storkebaum, 2002) ). Hence, the discovery of VEGF as a modifier of ALS was an unexpected coincidence. A transgenic mouse in which the 'hypoxia response element' in the promoter region of the VEGF gene was homozygously deleted (VEGF δ/δ mouse), revealed an important role for VEGF in the survival of motor neurons. These mice showed reduced VEGF expression and developed motor neuron loss, muscle weakness and a functional decline (Oosthuyse et al., 2001) . One possible explanation for this motor neuron degeneration is the loss of the neurotrophic effect of VEGF (Oosthuyse et al., 2001; Van Den Bosch et al., 2004) . In addition, considerable evidence for a more specific role of VEGF in ALS exists. The enhancement in disease severity after crossing the VEGF δ/δ mouse with the mutant SOD1 mouse (Lambrechts et al., 2003) , the lowered VEGF expression in the spinal cords of mutant SOD1 mice before disease onset (Lu et al., 2007) , the improvement of the phenotype when VEGF is genetically overexpressed in the same mouse model (Wang et al., 2007) and the rescue of the mutant phenotype in a zebrafish model after enhancing VEGF expression (Lemmens et al., 2007) , all point towards a modifying role of VEGF in ALS. Moreover, VEGF plays a role in the reduction of astrogliosis in the spinal cord , in the stabilization of the neuromuscular junctions in ALS mice and in the upregulation of the GluR2 subunit of the AMPA receptor (Bogaert et al., 2010) . As a consequence, the therapeutic potential of VEGF has been extensively explored in the mutant SOD1 rodent models. The delivery of viral vectors containing the human VEGF transgene into the muscle or the ventricular system increased the lifespan of the mutant SOD1 mice (Azzouz et al., 2004; Dodge et al., 2010) . Moreover, intracerebroventricular administration of VEGF ameliorated the phenotype of ALS rats (Storkebaum et al., 2005) . Finally, injecting genetically modified stem cells secreting this neurotrophic factor in ALS mice also resulted in beneficial effects (Hwang et al., 2009) . Currently, the intracerebroventricular delivery of VEGF is in a Phase I clinical study. Other homologous compounds could be considered in case that VEGF is not well tolerated in ALS patients, due to angiogenic side effects. One potent alternative is VEGF-B, a structural homolog of VEGF (Bogaert et al., 2006; Carmeliet and Storkebaum, 2002) . VEGF-B exerts similar neurotrophic effects in the mutant SOD1 mouse model, but has only weak angiogenic activity. Hence, the risk for toxic side effects is lower if a high therapeutic dose is required (Poesen et al., 2008) .
Mitochondrial dysfunction
Both in animal models and in ALS patients, dysfunctional mitochondria were observed. Mitochondria are multifunctional organelles involved in ATP synthesis, intracellular calcium homeostasis, apoptosis, etc. (Fig. 1) . Hence, abnormal functioning of mitochondria can cause cell dysfunction and subsequently cell death. In the mutant SOD1 mouse model, swollen and vacuolated mitochondria were observed in motor neurons and in skeletal muscle before the first signs of motor neuron degeneration appear (Higgins et al., 2003; Kong and Xu, 1998; Wong et al., 1995) . Similar abnormalities have been found in these tissues of sporadic ALS patients (Afifi et al., 1966; Sasaki and Iwata, 2007) . In general, dysfunctions in mitochondrial respiration and ATP synthesis, anterograde axonal transport of mitochondria, mitochondrial dynamics, calcium buffering and induction of apoptosis have all been observed in SOD1 mouse models (reviewed in (Kawamata and Manfredi, 2010) ). Moreover, these abnormalities are not restricted to mutant SOD1 pathogenesis as also in mice overexpressing human TDP-43 abnormal distribution of mitochondria and changes in mitochondrial dynamics have been described Xu et al., 2010) . Although the role of other diseasecausing genes in mitochondrial dynamics has been poorly investigated, smaller mitochondria were detected in neuronal cultures expressing ALS-linked FUS mutants (Tradewell et al., 2012) .
Because of the wide occurrence of mitochondrial dysfunction not only in mouse models with different causal mutations but also in sporadic patients, drugs that target these abnormalities are of therapeutic interest. Dexpramipexole, olesoxime and creatine, three compounds modulating mitochondrial function, showed promising results in preclinical studies, but failed in clinical trials (Bordet et al., 2007; Cudkowicz et al., 2013; Martin, 2010; Pastula et al., 2012; Shefner et al., 2004; Sunyach et al., 2012) . Currently, new strategies to improve mitochondrial function in ALS mice are explored. These include the inhibition of the caspase-1/cytochrome c/caspase-3 cell death pathway through melatonin administration (Zhang et al., 2013a) , disruption of the formation of toxic complexes formed after mutant SOD1 binding to mitochondrial proteins (Tan et al., 2013) and enhancing the mitochondrial calcium buffering capacity (Parone et al., 2013) . These studies seem to be promising so far.
Interestingly, peroxisome proliferator-activated receptor gamma coactivator-1α (PGC-1α), a transcriptional co-activator that can increase the number, the mass and the respiratory capacity of mitochondria in an ALS mouse model, is also a genetic modifier of ALS (Da Cruz et al., 2012; Eschbach et al., 2013). PGC-1α orchestrates the cellular response to metabolic demands by regulation of mitochondrial biogenesis, anti-oxidative defense, angiogenesis and autophagy (Da Cruz et al., 2012; Eschbach et al., 2013; Liang et al., 2011; Zhao et al., 2011) . PGC-1α mRNA was downregulated in the spinal cord and motor cortex of sporadic patients as well as in mutant SOD1 mice (Thau et al., 2012) . Interestingly, male ALS patients with a homozygous single nucleotide polymorphism (SNP) in the gene for PGC-1α (PPARGC1A) have an earlier disease onset and/or a shorter disease duration (Eschbach et al., 2013) . Moreover, a full deletion of PGC-1α in mutant SOD1 mice aggravated disease in males only, with an earlier onset and faster progression (Eschbach et al., 2013) , suggesting a gender-specific loss of function of PGC-1α in patients carrying a SNP in this gene. In line with the detrimental effect of a loss of PGC-1α in ALS mice, a general overexpression of human PGC-1α preserved motor neurons and neuromuscular junctions resulting in an increased survival of these mice Zhao et al., 2011) . These results point towards PGC-1α as an interesting therapeutic target for ALS.
Altered autophagy
Neurodegenerative diseases are frequently characterized by the appearance of intracellular protein aggregates that can be toxic for the cells and by the accumulation of dysfunctional organelles, such as mitochondria. Increasing the clearance of these aggregates and damaged organelles could be a possible therapeutic strategy in these diseases (Banerjee et al., 2010) . Autophagy and the ubiquitin-proteasome system (UPS) are the major clearance pathways in the cell. Both systems are responsible for the cellular homeostasis in eukaryotes and the prevention of accumulation of abnormal proteins. While the UPS is indispensable for the clearance of short-living proteins, the process of autophagy is important for the degradation of long-living proteins, abnormally folded proteins and for organelle turnover (Nixon, 2013) (Fig. 1) . Autophagy subtypes differ in the way that the substrate to be degraded is delivered to the lysosomes (Banerjee et al., 2010) . Macroautophagy, further referred to as autophagy, is the most studied subtype and it is characterized by the formation of a double-bilayered membrane that encloses a portion of the cytoplasm that contains the substrate that needs to be degraded. This results in the formation of a double-bilayered vesicle that is called the autophagosome (Wong and Cuervo, 2010) . In a later step of this process, autophagosomes fuse with lysosomes to degrade their cargo. When two essential genes for autophagy are ablated, mice develop a neurodegenerative phenotype which suggests an essential role of autophagy in neurons (Hara et al., 2006; Komatsu et al., 2006 ).
An increased number of autophagosomes are present in motor neurons of mutant SOD1 mice and sporadic ALS patients (Hetz et al., 2009; Li et al., 2008; Morimoto et al., 2007; Tian et al., 2011) . As autophagy is a multistep process, it can get disrupted at many different levels (Wong and Cuervo, 2010) . Whether this is a causal event, a result due to an upregulation of autophagy for the clearance of toxic proteins or due to a disrupted autophagosome-lysosome fusion is still not clear. Nevertheless, growing evidence suggests an overall impairment of autophagy in ALS. Mutations in the SQSTM1 and UBQLN2 genes, both involved in the regulation of autophagy, were discovered in sporadic and familial patients Fecto et al., 2011) . Transfection of cells with mutant UBQLN2 impaired autophagy, suggesting a loss of function mechanism for these mutations (Fecto et al., 2012) . Moreover, genetic stimulation of autophagy slowed down the disease progression in ALS mice (Hetz et al., 2009) . Different pharmacological approaches to stimulate autophagy have been tested. Two independent studies showed a negative effect on disease progression by treating mouse models of ALS with rapamycin, which is an FDA-approved drug that induces autophagy (Bhattacharya et al., 2012; Zhang et al., 2011) . This negative effect was probably due to the immunosuppressive function of rapamycin, as the disease could be slowed down in immunodeficient ALS mice . These results show that it is important to target autophagy with more specific compounds that do not have (negative) side-effects. Other compounds such as progesterone or trehalose, two activators of autophagy, have been administered to mutant SOD1 mice and showed promising results, such as delayed disease onset and longer survival which were correlated with an induction of the autophagic flux (Castillo et al., 2013; Kim et al., 2013; Zhang et al., 2014) . These data indicate that the modulation of autophagy can be a potential therapeutic strategy for ALS.
Impaired axonal transport
Because of their long projections, neurons are highly dependent on efficient axonal transport mechanisms to bring proteins, organelles and other cargoes to their sites of function or degradation. Microtubules form tracks along axons on which numerous cargoes can be transported with the help of motor proteins, which belong to the kinesin and the dynein protein family (Fig. 1) . These motor proteins hydrolyze ATP to move their cargoes along the microtubules (De Vos et al., 2008) . Since axonal swellings containing neurofilaments have been observed in sporadic and familial ALS patients (Okamoto et al., 1990; Sasaki and Maruyama, 1992) , axonal transport deficits have been intensively studied in the context of ALS (reviewed in (De Vos et al., 2008) ). In the mutant SOD1 mouse model, defects in axonal transport are an early event (Collard et al., 1995; De Vos et al., 2007; Kieran et al., 2005; Williamson and Cleveland, 1999; Zhang et al., 1997) . Moreover, point mutations in the p150 subunit of the dynactin 1 (DCTN1) gene were found in sporadic and familial ALS patients (Munch et al., 2004; Stockmann et al., 2013) . Dynactin stabilizes the binding of the cargo to the motor protein dynein (Millecamps and Julien, 2013) . Furthermore, dynactin is necessary for the function of dynein (LaMonte et al., 2002) . The disruption of the dynein/dynactin complex through the selective overexpression of a disassembler of dynactin in postnatal motor neurons of mice caused late-onset progressive motor neuron degeneration (LaMonte et al., 2002) . A knockdown of the homologue of dynactin 1 in a C. elegans model suggests that the observed motor neuron phenotype is due to impaired autophagosome transport (Ikenaka et al., 2013) . All together, these results suggests an active contribution of axonal transport deficits in motor neuron degeneration and more specifically also in ALS, as both the accumulation and site-specific loss of proteins, organelles and vesicles can lead to an aggravation of the phenotype. As a consequence, attempts to improve axonal transport can be possible therapeutic interventions (De Vos et al., 2008) .
One possible strategy to reach this goal could be the use of microtubule-modulating agents (Fanara et al., 2007; Jouroukhin et al., 2013) . In mutant SOD1 mice, microtubules are extremely unstable due to enhanced microtubule dynamics (Fanara et al., 2007) . When the assembly/disassembly cycle is occurring at abnormally high rates, the transport on this unstable road is severely impaired. Pharmacological modulation of hyperdynamic microtubules in mutant SOD1 mice recovered axonal transport, increased the survival of motor neurons and had a positive effect on the lifespan of the ALS mice (Fanara et al., 2007; Jouroukhin et al., 2013) .
A second strategy to improve axonal transport could be the enhancement of the α-tubulin acetylation. This approach has proven to be successful in different disease models including a mouse model of Charcot-Marie-Tooth disease (d 'Ydewalle et al., 2011) . Acetylation of α-tubulin promotes the recruitment of the motor proteins kinesin-1 and dynein to the microtubules. Histone deacetylase 6 (HDAC6) is an enzyme that can deacetylate α-tubulin, hence, inhibiting the function of this enzyme could improve axonal transport. However, HDAC6 also binds ubiquitin and enhances the microtubule transport mediated by dynein of ubiquitinated proteins to the autophagy machinery in the cell soma (Kawaguchi et al., 2003) . As a consequence, a proper balance of HDAC6 function is needed to maintain normal axonal transport and to ensure the elimination of misfolded proteins in neurodegenerative diseases. In the mutant SOD1 mouse model, the benefit on axonal transport by inhibiting HDAC6 function seems to outweigh the hazardous effect on removal of ubiquitinated proteins as the survival was significantly increased by genetic ablation of HDAC6 (Taes et al., 2013) or pharmacological inhibition of HDACs (Yoo and Ko, 2011) . These data suggest a possible beneficial effect on ALS progression by inhibition of the deacetylating function of HDAC6. As a consequence, the development and use of compounds selectively targeting the deacetylating function of HDAC6 could have therapeutic potential.
Axon retraction
Studies in rodent models and post-mortem patient tissue showed that axons from motor neurons can retract from the neuromuscular junction long before the loss of cell bodies (Fischer et al., 2004; Frey et al., 2000) . When an axon retracts from the muscle, nerve sprouting can occur in an attempt to form new compensatory connections. Synapses with low sprouting capacities are more vulnerable to degeneration, while axons with high sprouting capacity are more resistant (Frey et al., 2000) . From a therapeutic point of view, axonal retraction could be prevented by two different strategies: (1) induction of the sprouting capacity of axons or (2) preservation of the stability and functionality of neuromuscular junctions (Fig. 1) .
Improving axonal sprouting capacity
One option to improve the sprouting capacity could be the reduction of the inhibitory signals from the environment. Members of the netrin, ephrin, slit and semaphorin family can mediate these negative signals during axon guidance. A number of observations indicate that there is a link between these systems and ALS. First, the expression of the chemorepellent Semaphorin 3A (Sema3A) is induced in Schwann cells at the synapses that are most vulnerable to degeneration in the SOD1 model (De Winter et al., 2006) . Moreover, a missense mutation in the dihydropyrimidinase-like 3 (DPYSL3) or the collapsin response mediator protein 4a (CRMP4) gene was associated with ALS in a French population (Blasco et al., 2013) . This protein mediates the effects of semaphorins on axonal growth and neurite guidance (Blasco et al., 2013) . These observations suggest an active involvement of the inhibitory system in mediating the axonal sprouting properties of neurons.
In the ephrin system, the EphA4 receptor was identified as an ALS disease modifier in zebrafish, in rodent ALS models and in patients. This receptor is highly expressed during development where it has an axonal repellant function during the formation of the corticospinal tract (Dottori et al., 1998) and the peripheral projections to the hindlimbs (Eberhart et al., 2002) . In adult life, general expression decreases but EphA4 can still have a major contribution in pathological conditions (Goldshmit et al., 2004; Lemmens et al., 2013; Munro et al., 2013; Van Hoecke et al., 2012) . When EphA4 function was genetically ablated or pharmacologically inhibited in mutant SOD1 rodent models, disease onset and/or progression was slowed down. Moreover, the age of onset and survival inversely correlated with mRNA expression levels of EphA4 in blood of sporadic ALS patients (Van Hoecke et al., 2012) . Interestingly, EphA4 mRNA expression is highest in the large motor neurons of the spinal cord, which are the most vulnerable ones in ALS (Van Hoecke et al., 2012) . When EphA4 is deleted in the SOD1 mouse, the large motor neurons are protected. These data suggest a role for EphA4 in determining the vulnerability of motor neurons for degeneration in ALS. Moreover, the re-innervation of neuromuscular junctions after sciatic nerve axotomy in mice lacking EphA4 is significantly increased, suggesting that EphA4 could modify the regeneration capacity of motor axons (Van Hoecke et al., 2012) . In conclusion, targeting the ephrin system could be an interesting new therapeutic strategy for ALS.
Preservation of neuromuscular junctions
Apart from enhancing the sprouting capacity of axons to reinnervate muscles, preserving the integrity of the remaining neuromuscular junctions can also delay axonal retraction and subsequent dysfunction.
One approach could be to antagonize destabilizing proteins of the neuromuscular junctions. Nogo-A plays such a role in ALS. There is evidence that Nogo-A destabilizes the neuromuscular junctions during ALS. Throughout development, Nogo-A is expressed by different neuron types and is mainly localized in the growth cones of those with long axons (Schwab, 2010) . The expression of Nogo-A is lowered during adult life. Interestingly, Nogo-A is upregulated in spinal cord and muscle of mutant SOD1 mouse models (Dupuis et al., 2002) and also in muscle biopsies of ALS patients (Dupuis et al., 2002; Jokic et al., 2005) . The upregulation correlates with the severity of muscle atrophy and motor function impairment in patients (Dupuis et al., 2002; Jokic et al., 2005) . When Nogo-A is deleted in the mutant SOD1 mouse, survival is significantly increased (Jokic et al., 2006) . On the pathological level, denervation of the neuromuscular junctions and motor neuron degeneration were delayed. In contrast, overexpression of Nogo-A in muscle fibers of wild type mice destabilized neuromuscular junctions and caused retraction of the nerve terminal (Jokic et al., 2006) . This suggests that the higher expression of Nogo-A detected in skeletal muscle fibers of ALS patients could affect the integrity of neuromuscular junctions and that this could be followed by the destabilization and retraction of the nerve ends. This could cause the retrograde axon pathology that will result in the death of the motor neuron. Currently, intravenous administration of an anti-Nogo-A antibody (Ozanezumab) is in a Phase II clinical trial.
Translation of biological findings into new therapies
Despite all the recent insights into the molecular mechanism of the disease, no improvement in the therapeutic options for ALS patients has been obtained during the past 20 years. Only the effect of riluzole has been confirmed in different clinical trials (Bensimon et al., 1994 (Bensimon et al., , 2002 Lacomblez et al., 1996; Yanagisawa and Shindo, 1996) . As indicated by a number of examples in this review, a large number of preclinical studies have been performed in rodent models of ALS to prevent, reverse or modulate the disease process. So far, none of these therapeutic strategies has been successfully replicated in clinical trials. As a consequence, besides riluzole, only symptomatic treatments are applied to improve the quality of life of ALS patients. Those treatments are based on multidisciplinary care and also include the use of non-invasive ventilation and early percutaneous endoscopic gastrostomy (Traynor et al., 2003; Van Damme and Robberecht, 2009) .
In this part of the review, we will discuss how the translational step can be improved at the preclinical level.
Investigation of new pathogenic pathways
Recent discoveries in the ALS field resulted in a paradigm shift, which will have an important impact on the development of new therapeutic strategies. It becomes more and more clear that many genes linked to ALS encode for RNA/DNA binding proteins and/or influence RNA metabolism. The identification of mutations in genes for TDP-43, FUS and C9ORF72 led to the idea that aberrant RNA metabolism plays a crucial role in ALS pathogenesis (reviewed in (Lemmens et al., 2010) ). These insights shifted the focus from 'ALS as a proteinopathy' to 'ALS as a ribonucleopathy' .
A lot of attention is focused on TDP-43, as the protein is present in ubiquitinated cytoplasmic neuronal inclusions in most patients with ALS (Neumann et al., 2006) . TDP-43 is mainly present in the nucleus where it is involved in transcription, RNA splicing and micro-RNA processing (Lee et al., 2012a) . The protein can shuttle between the nucleus and the cytoplasm. In the cytoplasm, TDP-43 is associated with transport granules in which mRNA is transported to the sites of translation (Fallini et al., 2012) . In conditions of cellular stress, TDP-43 is incorporated in cytoplasmic stress granules until stress is resolved (Dewey et al., 2011; McDonald et al., 2011) . ALS-associated mutations seem to induce a shift of TDP-43 from the nucleus to the cytoplasm, where aggregates are formed (Johnson et al., 2009) .
Like TDP-43, FUS is an RNA-binding protein involved in different processes of RNA metabolism. It is mainly localized in the nucleus, but it is also present in the cytoplasm and at postsynaptic densities (Aoki et al., 2012; Zinszner et al., 1997) . Most ALS-linked mutations disrupt nuclear import, inducing the mislocalization of FUS in stress granules and in inclusions (Dormann et al., 2010) . These FUS-positive inclusions are observed in brain and spinal cord of patients with FUS mutations (Kwiatkowski et al., 2009; Vance et al., 2009) .
Both TDP-43 and FUS target more than 5000 mRNAs (Lagier-Tourenne et al., 2012; Polymenidou et al., 2011) , which emphasizes their important role in normal cell functioning. However, it is still a matter of debate whether the depletion of these proteins from the nucleus (loss of function), the increased cytoplasmic aggregation propensity (gain of function), or both are involved in disease pathogenesis (reviewed in (Lee et al., 2012a) ). Screens for the detection of modifiers of TDP-43 and FUS toxicity in cell systems, yeast and/or Drosophila, have identified some modifiers of both TDP-43 and/or FUS toxicity, e.g. ataxin-2 (ATXN2) and 'debranching enzyme homologue 1' (DBR1) (Armakola et al., 2012; Elden et al., 2010) .
In 2012, a major breakthrough in ALS genetics was the discovery of hexanucleotide repeat expansions in the C9ORF72 gene as a common cause of ALS (DeJesus-Hernandez et al., 2011; Renton et al., 2011) . The physiological function of the gene product is still unknown, but the protein is structurally related to DENN proteins, which are GDP/GTP exchange factors (GEFs) implicated in membrane trafficking (Levine et al., 2013) . How these repeat expansions can cause ALS is intriguing the ALS research field. As C9ORF72 mRNA levels are reduced in samples of patients carrying the repeat expansion, a loss of function mechanism is possible (DeJesus-Hernandez et al., 2011; Gijselinck et al., 2012) . This could be due to ineffective transcription of DNA carrying the repeat. In contrast, repeat containing RNA foci in patients, suggest a deleterious gain of function (DeJesus-Hernandez et al., 2011) . Repeats are able to form G-quadruplexes (Fratta et al., 2012; Reddy et al., 2013) , which may be able to facilitate the binding and sequestration of different RNA binding proteins to the repeat . Subsequently, these proteins are not able anymore to execute their normal functions. A third mechanism is the possible occurrence of repeat-associated non-ATG (RAN) translation along the hairpin-forming repeat. This results in aggregates containing different dipeptide repeat proteins (DPRs) in patients with the C9ORF72 repeat expansion Gendron et al., 2013; Mori et al., 2013a Mori et al., , 2013b .
Before one can translate these findings into new causal or modifying therapies, better insights into the exact pathogenic mechanisms are essential. However, it is clear that these new insights in TDP-43, FUS and C9ORF72 pathology will result in the development of a completely new class of therapeutic strategies.
Development of new disease models
The best currently available animal models of ALS are the mutant SOD1 mouse and rat models that recapitulate the human disease process. Hence, almost all preclinical research is performed using these models. However, SOD1 mutations are only causing disease in approximately 20% of familial ALS patients and as a consequence this model is, from a genetic point of view, only representative for about 2% of total ALS patients. Thus, one should be cautious before translating experimental findings from this model to humans, as the ALS patient population is very heterogeneous and contains both sporadic and familial cases with a wide range of different mutated genes. To enlarge the basis before starting a clinical trial, different models with different ALScausing mutations are needed. Moreover, these new models can also provide us with more and better insights into the pathological mechanism(s) caused by mutant TDP-43, FUS and C9ORF72.
Although great efforts were made to obtain new rodent models, the generated ones do not represent the progressive neurodegeneration and pathology observed in the human disease so far (McGoldrick et al., 2013) . While waiting for new rodent models, alternative model organisms such as yeast, Drosophila and zebrafish can be used (Elden et al., 2010; Lemmens et al., 2007) . These alternative model organisms have the additional advantage in comparison to rodent models that more therapeutic approaches can be screened (Giacomotto and Segalat, 2010; Lemmens et al., 2007) .
Besides model organisms, human iPSCs give the opportunity to develop cultured human neuronal cells carrying different diseasecausing mutations, partially representing the genetic variability occurring in patients. These are adult pluripotent stem cells generated from somatic cells by the overexpression of different reprogramming/ transcription factors, and can be forced to differentiate into different cell types by the use of specific growth factors and cell culture conditions (Dolmetsch and Geschwind, 2011) . IPSCs from patients with different disease-causing mutations have already been developed, which include mutations in the SOD1, vesicle-associated membrane protein-associated protein B/C (VAPB), TDP-43 and C9ORF72 genes (Almeida et al., 2013; Bilican et al., 2012; Dimos et al., 2008; Donnelly et al., 2013; Egawa et al., 2012; Sareen et al., 2013; Zhang et al., 2013b) . Moreover, iPSC-derived motor neurons from sporadic patients with TDP-43 pathology have also been obtained (Burkhardt et al., 2013) . Although iPSC-derived neurons give the opportunity to study human-derived neuronal cells, they cannot replace whole-organism models as these cells lack the anatomical and biological context. One way to (partially) overcome this problem is to perform studies on mixed cell cultures containing different cell types.
Reproducibility of experiments in rodent models
One problem to translate preclinical findings into new treatments for patients is the lack of reproducibility of the preclinical studies. Recently, the ALS Therapy Development Institute (TDI) retested different compounds with a reported beneficial effect in the mutant SOD1 mouse model. Unfortunately, TDI was unable to obtain any beneficial effect (Perrin, 2014) . As this was not the first study in which a positive effect could not be reproduced (Scott et al., 2008) , it is extremely important to improve the robustness of preclinical studies.
Standardized protocols should be followed in order to improve the comparability between different laboratories of the outcome of a treatment. Consensus guidelines have been written in order to avoid the lack of reproducibility (Ludolph et al., 2010 ) and should be conscientiously followed. These guidelines include the description of measurements to determine onset, disease progression and end stage. These different parameters should be always measured to determine whether a therapeutic approach successfully modulates the disease process. More than one technique should be used to assess onset and disease progression and if there is a positive outcome it should be accompanied by a histological assessment. Motor neuron counts in the spinal cord and evaluation of the neuromuscular junction integrity are important to interpret the positive effect of a potential therapy. Moreover, performing the preclinical studies by an experimenter blinded for the treatment condition and using always the proper controls (age-and gendermatched) will also increase the robustness of the experimental outcome.
Phenotypic variability could be another source for the lack of reproducibility. One important reason for this variability is the unstable inheritance of the number of overexpressed SOD1 copies, as this is an important determinant of disease onset and life span. As a consequence, quantification of the number of SOD1 gene copies by quantitative PCR (qPCR) and/or a rigorous follow-up of the life span of the transgenic breeders is important to maintain a homogeneous cohort without copy number loss.
In conclusion, a detailed report of the outcome, methodology and the characteristics of the mouse cohort that was used in a preclinical study is crucial to interpret the validity of any published preclinical study.
Optimization of the experimental design
A proper design of a preclinical experiment is of great importance to predict the translational potential of a therapeutic approach.
First, the number of animals in an experimental group should be sufficient to overcome the intrinsic phenotypic variability. In order to limit this variation, littermate controls should be used. In order to estimate the number of animals needed, a statistical power calculation based on the expected variability and the predicted therapeutic effect should be performed.
Second, the pharmacokinetics of the compound should be determined in order to estimate the proper dose of the drug. Moreover, it is very important to check whether the drug is reaching the target tissue.
Third, the treatment strategy of a compound in a rodent model should resemble as much as possible the situation in the clinic. The time point and the mode of administration are the two most important parameters in relation to this issue. In preclinical experiments, treatment is most often started before the phenotypic onset of the disease. This is not a feasible therapeutic strategy for sporadic ALS patients. As a consequence, it is important that the administration of a compound in a preclinical trial is also performed at an age that is closer to onset or even after the onset of symptoms.
Finally, the mode of administration should be chosen based on the intrinsic properties of the compound. As many compounds have low bloodbrain barrier permeability or can induce peripheral side effects, the classical administration by intraperitoneal injections or oral gavage is not always the most optimal one. In these cases, alternative delivery strategies should be considered. These alternative strategies have been extensively and successfully explored in mutant SOD1 rodent models for the administration of neurotrophic factors. Administration of neurotrophic factors intrathecally, intracerebroventricularly, in specific areas of the spinal cord or in the muscle leads to the preservation of motor neurons and/or axonal integrity in ALS rodent models and to an attenuation of the disease process (Acsadi et al., 2002; Azzouz et al., 2004; Dobrowolny et al., 2005; Dodge et al., 2010; Franz et al., 2009; Hwang et al., 2009; Kaspar et al., 2003; Lepore et al., 2007; Nagano et al., 2005; Park et al., 2009; Storkebaum et al., 2005; Suzuki et al., 2007 .
Validation and amelioration of the therapeutic target
Whenever a possible therapeutic target is discovered, the molecular mechanism(s) by which the therapeutic effect is caused should be investigated. This will not only generate new insights into the disease mechanism(s) but also increase the number of possible therapeutic targets. It could be easier to develop compounds for another target within the same pathway modulating the same pathogenic process as the original one (e.g. targeting an enzyme versus a structural protein) or it might be possible that better compounds directed against these new targets already exist.
Conclusions
During the last decade, the knowledge about the biological mechanisms that could be involved in ALS has substantially improved. Both additional causal genes and new pathological processes underlying the selective motor neuron death were identified. Developing a causal therapy that targets a specific disease-causing gene can have a huge effect by preventing the pathological events responsible for the disease. However, only a limited number of patients affected by ALS will benefit from this therapy. The alternative approach is to target pathogenic processes such as astrocytosis, neuroinflammation, mitochondrial dysfunction, deregulated autophagy, and/or axonal transport dysfunction and retraction that commonly arise in patients with different ALS etiologies. Most likely, the effect of such a modifying treatment will be smaller compared to that of a causal treatment, but the target population will be larger as all ALS patients could benefit from this treatment. In order to achieve a more prominent effect, different modifying therapies could be combined in order to have an additive and hopefully even a synergistic effect.
